Amylyx Stock Soars 13.97% on Bullish Analyst Upgrades

On June 10, 2025, Amylyx's stock surged by 13.97% in pre-market trading, marking a significant rise that has caught the attention of investors and analysts alike.

HC Wainwright, a prominent investment bank, has recently adjusted its stance on Amylyx Pharmaceuticals. The firm raised its price target for the company from $12.00 to $16.00 and maintained a "buy" rating, reflecting a bullish outlook on the stock's future performance.

Wellington Management Group LLP has also made a notable move by purchasing a new stake in Amylyx Pharmaceuticals. This acquisition indicates a growing interest from institutional investors, who are likely attracted to the company's potential for growth and innovation in the pharmaceutical sector.